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Glioblastoma, the most common primary malignant cancer of the
brain, is characterized by rapid tumor growth and inﬁltration of
tumor cells throughout the brain. These traits cause glioblastomas
to be highly resistant to current therapies with a resultant poor
prognosis. Although aberrant oncogenic signaling driven by signa-
ture genetic alterations, such as EGF receptor (EGFR) gene ampliﬁca-
tion and mutation, plays a major role in glioblastoma pathogenesis,
the responsible downstream mechanisms remain less clear. Here,
we report that EGFRvIII (also known as ΔEGFR and de2-7EGFR),
a constitutively active EGFR mutant that is frequently co-overex-
pressed with EGFR in human glioblastoma, promotes tumorigene-
sis through Src family kinase (SFK)-dependent phosphorylation of
Dock180, a guanine nucleotide exchange factor for Rac1. EGFRvIII
induces phosphorylation of Dock180 at tyrosine residue 722
(Dock180Y722) and stimulates Rac1-signaling, glioblastoma cell sur-
vival andmigration. Consistentwith this being causal, siRNA knock-
down of Dock180 or expression of a Dock180Y722F mutant inhibits
each of these EGFRvIII-stimulated activities. The SFKs, Src, Fyn, and
Lyn, induce phosphorylation of Dock180Y722 and inhibition of these
SFKs by pharmacological inhibitors or shRNA depletion markedly
attenuates EGFRvIII-induced phosphorylation of Dock180Y722, Rac1
activity, and glioblastoma cell migration. Finally, phosphorylated
Dock180Y722 is coexpressed with EGFRvIII and phosphorylated
SrcY418 in clinical specimens, and such coexpression correlates with
an extremely poor survival in glioblastoma patients. These results
suggest that targeting the SFK-p-Dock180Y722-Rac1 signaling path-
way may offer a novel therapeutic strategy for glioblastomas with
EGFRvIII overexpression.
invasion | Akt
Oncogenic signaling stimulated by overexpressed genes, suchas EGF receptor (EGFR), renders human brain glioblasto-
mas malignant and resistant to combination therapies (1). Am-
pliﬁcation of EGFR is the most frequent genetic alteration in
World Health Organization (WHO) grade IV glioblastoma mul-
tiforme (GBM) (2, 3) and is associated with poor prognosis (1).
About half of GBMs with EGFR ampliﬁcation also express the
mutant form, EGFRvIII/ΔEGFR/de2-7EGFR, that lacks a por-
tion of the extracellular ligand-binding domain (encoded by exons
2 through 7), leading to constitutively activated oncogenic sig-
naling (3, 4). Expression of EGFRvIII enhances glioblastoma
tumorigenicity in vivo (5) and promotes glioblastoma cell motility
in vitro (6). Although EGFRvIII activates PI3K/Akt signaling,
other signaling cascades are also likely involved in mediating
EGFRvIII-driven tumorigenesis (3, 4).
Dedicator of cytokinesis 1 (Dock1 or Dock180) is a guanine
nucleotide exchange factor (GEF) that activates Rac1 and controls
several cellular functions, including cell motility, survival, and
proliferation (7). Dock180 facilitates nucleotide exchange on Rac1
through its Dock-homology region-2 (DHR-2) domain, but re-
quires binding to engulfment and cell motility protein 1 (ELMO1)
through its N-terminal SH3 domain to achieve full activation of
Rac1 (8). Adjacent to the SH3 region resides a DHR-1 domain
which interacts with phosphatidyl-inositol(3,4,5)P3 (PIP3), and
therebymediates the localization ofDock180 to the cell membrane
sites of PIP3 production where Dock180 subsequently activates
Rac1 through its DHR-2 domain (8). Although genomic studies
have revealed no genetic alterations in Rac1, Dock180, or ELMO1
in various human cancers, including glioblastoma, it remains pos-
sible, given its central role in regulating cellular functions, that
GEF-Rac1 signaling is stimulated by signals emanating from acti-
vated oncogenes, such as EGFRvIII.
GEF activation by receptor tyrosine kinases (RTK) stimulates
Rac1 (9) and may be important in EGFRvIII-driven tumorigen-
esis (3). Dock180 activates Rac1 (8) and is involved in RTK-in-
duced cell migration inDrosophila (10), and Dock180 plays a role
in glioblastoma cell invasion through the activation of Rac1 (11).
Here, we report that EGFRvIII induces tyrosine phosphorylation
(p-Y) at tyrosine residue 722 (Y722) of Dock180, and that
Dock180 and its phosphorylation are required for EGFRvIII-
promoted glioblastoma cell growth, survival, and invasion.
Correspondingly, ectopic expression of an unphosphorylatable
Dock180Y722F mutant inhibited EGFRvIII-induced Rac1 activa-
tion, cell migration, and survival in vitro, and glioblastoma growth
and invasion in the brain. We also report that EGFRvIII-induced
p-Dock180Y722 is dependent on Src family kinases (SFKs), that
p-Dock180Y722 is coexpressed with EGFRvIII and pan-p-SrcY418
in clinical glioblastoma specimens, and that such coexpression
correlates with an extremely poor prognosis.
Results
Dock180 Is Required for EGFRvIII-Promoted Glioblastoma Cell
Migration and Survival in Vitro. To determine if EGFRvIII sig-
naling engages Dock180 as part of its oncogenic mechanism, we
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stably expressed exogenous EGFRvIII in glioblastoma LN444/
GFP and SNB19/GFP cells that have high levels of endogenous
Dock180 (11). Expression of EGFRvIII in LN444 and SNB19
glioblastoma cells induced p-EGFRvIII, p-Akt, p-Erk1/2, and
Rac1 activity (Fig. 1A), increased in vitro cell migration (Fig.
1B), proliferation (Fig. S1 A and B), and markedly inhibited cell
apoptosis (Fig. S1C).
We recently reported that Dock180 promotes glioblastoma cell
invasion through activation of Rac1 (11). To determine whether
this function of Dock180 is required for EGFRvIII-stimulated glio-
blastoma tumorigenesis, we knocked down endogenous Dock180
using siRNAs (11) in each of LN444/GFP, LN444/GFP/EGFR-
vIII, SNB19/GFP, and SNB19/GFP/EGFRvIII cells. As shown in
Fig. 1C, knockdown of Dock180 in EGFRvIII-expressing cells
inhibited EGFRvIII-induced p-Akt, p-Erk1/2, and Rac1 activity.
Depletion of Dock180 also suppressed basal Rac1 activity in GFP
control cells (11). Knockdown of Dock180 attenuated EGFRvIII-
promoted cell migration and survival in EGFRvIII-expressing cells
and basal levels of cell migration in GFP control cells (Fig. 1D and
E). However, depletion of Dock180 had only moderate effects on
cell proliferation in both EGFRvIII- and GFP-expressing cells
(Fig. 1 F and G). These data suggest that Dock180 is critical for
EGFRvIII-stimulated p-Akt, p-Erk1/2, and Rac1 activity, as well
as for glioblastoma cell migration and survival in vitro.
EGFRvIII Induces p-Y of Dock180 at Y722. We examined whether
EGFRvIII phosphorylates Dock180 at Y residues in glioblastoma
cells. As shown in Fig. 2A, p-Y of endogenous Dock180 was ev-
ident in both LN444/EGFRvIII and SNB19/EGFRvIII cells, but
not in GFP-expressing cells. To identify the Y residues of
Dock180 that are phosphorylated by EGFRvIII, we generated
Flag-tagged WT and six different Dock180 mutants that lack
DHR-1, -2, or other regions (Fig. 2B). When EGFRvIII and WT
Dock180 were coexpressed in HEK293T cells, EGFRvIII in-
duced p-Y of WT Dock180, whereas expression of either protein
alone did not result in p-Y of Dock180 (Fig. 2C). Next, we
coexpressed EGFRvIII with WT or the six individual mutants of
Dock180 and found a marked reduction of EGFRvIII-induced
p-Y of the Dock180 Del-6 mutant but not the Dock180 WT or
other Del mutants (Fig. 2D, blue arrows), suggesting that the p-Y
sites are located between amino acid residues 602 and 805 (Fig.
2B). In this region, there are six Y residues: Y700, Y712, Y722,
Y736, Y760, and Y780. To identify which Y residue is phos-
phorylated by EGFRvIII, we individually mutated each of these
six Y residues to a phenylalanine (F) in the Dock180 Del-5 mu-
tant. When these six Del-5 YF mutants or the Del-5 mutant were
separately coexpressed with EGFRvIII in HEK293T cells,
EGFRvIII induced p-Y of all Dock180 mutants except Del-5/
F722, suggestive of Y722 as a potential p-Y site by EGFRvIII
(Fig. 2E). To further validate this ﬁnding, we generated an Y722F
mutation in the full-length Dock180 protein (Dock180Y722F).
Coexpression of EGFRvIII with Dock180Y722F showed a more
than 40% reduction in p-Y levels compared with that of
Dock180WT (Fig. 2F). These data suggest that Y722 is a major p-
Y site induced by EGFRvIII, and that there are additional p-Y
sites within Dock180 because of EGFRvIII activity to a lesser
extent. Next, we compared amino acid sequences surrounding
Y722 in Dock180 in various species and the other four members
of the Dock family, and found that Y722 and most of its sur-
rounding residues are highly conserved among them (Fig. 2G).
Phosphorylation of Dock180Y722 Is Required for EGFRvIII-Promoted
Glioblastoma Tumorigenesis. We generated a rabbit polyclonal an-
tibody that speciﬁcally recognizes the p-Dock180Y722 protein. This
anti–p-Dock180Y722 antibody detected EGF (but not PDGF or
HGF) induced p-Y of endogenousDock180 in SNB19,U87,U373,
and LN444 glioblastoma cells at various levels (Fig. 3A). We then
knocked downDock180 in SNB19 or SNB19/EGFRvIII cells using
an siRNA pool for Dock180 or a control siRNA (11), and found
that depletion of endogenous Dock180 by the siRNA pool, but not
control siRNA, signiﬁcantly diminished the EGFRvIII-induced
p-Dock180Y722 in SNB19/EGFRvIII cells whereas no signal was
seen in SNB19 cells (Fig S2 A and B). These results validate the
speciﬁcity of this antibody in detecting EGFRvIII-induced p-Y722
of endogenous Dock180 in glioblastoma cells. Next, we stably
transfected Flag-tagged Dock180WT or Dock180Y722F into
EGFRvIII-expressing SNB19 and LN444 glioblastoma cells. As
shown in Fig. 3B, ectopic expression of Dock180WT did not affect
EGFRvIII stimulation of p-Akt, p-Erk1/2, and Rac1 activity in
SNB19/EGFRvIII and LN444/EGFRvIII cells. In contrast, ex-
pression of Dock180Y722F markedly reduced EGFRvIII-induced
p-Akt, p-Erk1/2, and Rac1 activity. Additionally, Dock180Y722F
but not Dock180WT signiﬁcantly attenuated EGFRvIII-stimulated
glioblastoma cell survival and migration in vitro (Fig. S3 A and B).
However, expression of Dock180WT or Dock180Y722F had only a
moderate impact on in vitro proliferation in both LN444/EGFR-
vIII and SNB19/EGFRvIII cells (Fig. S3 C and D).
We then separately implanted SNB19/EGFRvIII/Dock180WT,
SNB19/EGFRvIII/Dock180Y722F, or the control SNB19/EGFRvIII/
GFP cells into the brains of mice. As described previously (12),
SNB19/GFP cells formed small but invasive tumors in the brains of
mice. Moreover, mice that received SNB19/EGFRvIII/GFP cells
showed markedly enhanced tumor growth and invasion, whereas
mice that received SNB19/EGFRvIII/Dock180WT cells also de-
veloped brain tumors with large volumes and similar invasiveness
(Fig. 3C and Fig. S4 A–C), suggesting no further enhancement by
Dock180WT expression. In contrast, mice that received SNB19/
EGFRvIII/Dock180Y722F cells developed much smaller and less
invasive tumors (Fig. 3C and Fig. S4 A–C). In addition, expression
of Dock180WT had no signiﬁcant effect on glioblastoma cell pro-










































































































































































Fig. 1. Dock180 is required for EGFRvIII-induced Rac1 activity, glioblastoma
cell migration, and survival in vitro. (A) IB analyses. (B and D) In vitro cell
migration assays. Data are presented as percentage of control cells. (C) IB
analyses. C, control siRNA; D1, Dock180 siRNA pool. In A and C, β-actin, Akt,
Erk1/2, and Rac1 were used as loading controls. (E) Cell apoptosis. Data are
presented as percentage of apoptotic cells. (F and G) Cell proliferation; data
were calculated by dividing the total cell number by 50,000 and converting it
to a log2 value. Data in B and D–G were from six replicates per pair per cell
line. Data are representative from three independent experiments with
similar results. *P < 0.05. (Scale bars, ± SD.)














and Fig. S4A). However, expression of Dock180Y722F signiﬁ-
cantly suppressed EGFRvIII-stimulated glioblastoma cell pro-
liferation and survival compared with SNB19/EGFRvIII/GFP
or SNB19/EGFRvIII/Dock180WT tumors (Fig. 3 D and E and
Fig. S4A). These data suggest that p-Dock180Y722 is important
for EGFRvIII-promoted glioblastoma tumorigenesis in vivo and
that Dock180Y722F acts in a dominant negative fashion to inhibit
EGFRvIII-driven tumorigenicity.
SFKs Are Responsible for EGFRvIII-Induced p-Dock180Y722. We next
performed in silico analyses (http://scansite.mit.edu) and found
that Y722 of Dock180 is a potential p-Y site for Src. To de-
termine whether Src and other SFKs are involved in EGFRvIII-
stimulated p-Dock180Y722 and cell migration, we ﬁrst treated
LN444/EGFRvIII and SNB19/EGFRvIII cells with two pharma-
cological inhibitors of SFKs (SU6656, PP2) or a vehicle control.
As shown in Fig. 4 A and B, both PP2 and SU6656 effectively
inhibited EGFRvIII-induced p-Y of Dock180, Rac1 activity, pan
p-Y of SrcY418, and EGFRvIII-stimulated cell migration.
Next, we coexpressed WT, kinase dead (KD) or constitutively
activated (CA) Src with ﬂag-tagged Dock180WT or Dock180Y722F
in HEK293T cells. WT or CA Src induced p-Y of Dock180WT to
higher levels compared with that of Dock180Y722F, whereas KD
Src had no effect on p-Y of Dock180WT or Dock180Y722F. As
expected, CA Src displayed higher kinase activity on p-Y of
Dock180 than did WT Src (Fig. 4C). We then tested whether the
dominant negative KD Src mutant inhibits the EGFRvIII-in-





HUMAN       714 KLTKVLKNYVDGAE 727
Monkey      763 KLTKVLKNYVDGAE 776
Chimpanzee  335 KLTKVLKNYVDGAE 348
Horse       708 KLTKVLRNYVDNAE 721
Dog         705 KLTKVLRNYVDNAE 718
Cow         743 KLTKVLRNYVDNAE 756
Rat         715 KLTKVLRTYVASAE 728
Mouse       715 KLTKVLRTYVASAE 728
Chicken     722 KLTKVLKTYVDNAE 735
Zebra finch 733 KLTKVLKTYVDNAE 746
Zebrafish 713 KLTKVLKNYVDNAE 726
G
DOCK180 714  KLTKVLKNYVDGAE 727
DOCK2   713  KLMTVLKTYLDTSS 726
DOCK3   358  ELIRCLKWYMDCSA 371
DOCK4   678  DLIKVLKWYVDRIT 691
DOCK5   733  KLSKVLNFYVANAD 746
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Fig. 2. EGFRvIII induces p-Y of Dock180 at
Y722. (A) IP and IB analyses. (B) Schematic
of deletionmutants of Dock180. (C) EGFRvIII
induces p-Y of Dock180 in HEK293T cells.
(D) IB analyses. Red arrows, IgG; bluearrows,
p-Y of Del mutant. (E) Mutation of Y722F in
Del-5 decreased p-Y of Dock180. (F) Y722
is a major EGFRvIII-induced p-Y site in
Dock180. (Scale bars, ± SD.) Bar graph un-
derneath: relative amount of p-Y of
Dock180 was determined from three sep-
arate in IP-IB blots by ImageJ and normal-
ized to the amount of Dock180. *P < 0.05.
(G) Y722 is conserved in Dock180 of vari-
ous species and in Dock protein family.
Black, conserved amino acids; blue, non-
conserved amino acids. In A and C–F, a
pan-phospho-tyrosine antibody was used
to detect p-Y-Dock180. Data are represen-
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Fig. 3. Phosphorylation of Dock180Y722 is critical for
EGFRvIII-driven glioblastoma growth and invasion. (A)
EGF, but not PDGF-A or HGF, induces p-Y of endogenous
Dock180Y722 (detected with a speciﬁc anti–p-Dock180Y722
antibody) in glioblastoma cells. (B) Effect of Dock180WT,
Dock180Y722F, or a vector control on p-Dock180Y722, p-
Akt, p-Erk1/2, and Rac1 activity in EGFRvIII-expressing
cells. Dock180, Akt, Erk1/2, Rac1, and β-actin were used as
loading controls. (C) Dock180Y722F inhibits EGFRvIII-pro-
moted glioblastoma growth and invasion in the brain.
Representative H&E and IHC images of brain sections of
mice receiving various SNB19 cells (8 wk postinjection,
ﬁve mice per group). (a–c) H&E staining. (Scale bars,
1 mm.) (d–f) Enlarged areas in a to c marked with
squares. (Scale bars, 200 μm.) (g–i) GFP images of the
same areas in d to f. (Scale bars, 200 μm.) Arrows indicate
invasive tumor cells (d–i). (D and E) Quantiﬁcation of Ki-
67 and TUNEL staining, respectively. *P < 0.05. (Scale
bars, ± SD.) Data represent three independent experi-
ments with similar results.
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Src with EGFRvIII and Dock180 partially blocked EGFRvIII-
induced p-Y of both Dock180WT and Dock180Y722F compared
with controls. These results are consistent with partial attenua-
tion of EGFRvIII-induced p-Y by the Dock180Y722F mutant,
suggesting that there are other p-Y sites on Dock180 stimulated
by EGFRvIII through other kinases.
To validate direct Src phosphorylation of Dock180Y722, we
performed in vitro p-Y assays by incubating puriﬁed recombinant
(His)6-Dock180
WT or (His)6-Dock180
Y722F proteins with a re-
combinant active Src followed by immunoblot (IB) using the
speciﬁc anti–p-Dock180Y722 antibody. As shown in Fig. 4E,
a recombinant Src effectively induced p-Y of Dock180WT but not
Dock180Y722F in vitro. Next, we evaluated the impact of Src-
induced p-Y of Dock180 on its interaction with Rac1 using an
in vitro reconstitution assay. In the absence of the recombinant
Src, when immunoprecipitated Dock180WT or Dock180Y722F
from HEK293T was dephosphorylated by a protein tyrosine
phosphatase, p-Y of Y722 of Dock180 was undetectable and
minimal Dock180–Rac1 interaction was observed. However,
when a recombinant Src was added, p-Dock180WT but not p-
Dock180Y722F was signiﬁcantly induced, accompanied with an
increase in association of Dock180 with Rac1 (Fig. 4F).
Then, we stably knocked down endogenous Src using two dif-
ferent shRNAs in SNB19/EGFRvIII cells that expressed either
Dock180WT or Dock180Y722F. An ∼75% reduction of Src in
SNB19/EGFRvIII cells markedly attenuated EGFRvIII-stimu-
lated p-Y722 of Dock180, Rac1 activity (Fig. 4G) and cell mi-
gration (Fig. 4H) in vector control and Dock180WT-expressing
cells, but had a minimal impact on Dock180Y722F-expressing cells.
Additionally, expression of Dock180WT had minimal impact,
whereas Dock180Y722F suppressed EGFRvIII stimulation of p-
Dock180Y722, Rac1 activity, and cell migration (Fig. 4 G and H).
Finally, we determined whether two other SFKs, Fyn and Lyn
(13, 14), are involved in EGFRvIII-stimulated Dock180 phos-
phorylation. We knocked down endogenous Fyn or Lyn using
two separate shRNAs for each protein in SNB19/EGFRvIII cells
that express Dock180WT, Dock180Y722F, or a vector control. As
shown in Fig. 5 A–C, shRNA knockdown of Fyn or Lyn markedly
decreased EGFRvIII-induced p-Y722 of Dock180WT, Rac1 ac-
tivity, and cell migration in SNB19/EGFRvIII/vector and SNB19/
EGFRvIII/Dock180WT cells, but did not affect EGFRvIII stim-
ulation of SNB19/EGFRvIII/Dock180Y722F cells (Fig. 5). These
data demonstrate that SFKs, Src, Fyn, and Lyn largely mediate
EGFRvIII stimulation of Rac1 activity and glioblastoma cell
migration through p-Y722 of Dock180.
SFKs Stimulate p-Dock180Y722, Rac1 Activity, and Cell Migration of
Primary Human GBM Cells That Overexpress EGFRvIII. Next, we de-
termined whether SFKs also induce p-Y of Dock180Y722, Rac1
activity, and cell migration in primary human GBM cells. To this
end, we examined cells from four different serially transplanted
human GBMs, GBM6, GBM39, GBM12, and GBM14 cells that
retain the EGFR status of the primary tumor from which they
were derived (15). In GBM6 and GBM39 that retained EGFRvIII
overexpression, strong p-Y of Dock180Y722 and Rac1 activity were
found (Fig. S5A). In contrast, without EGF stimulation, neither
p-Y722 of Dock180 nor increased Rac1 activity was detected in
GBM12 cells that express WT EGFR or GBM14 cells that have
nondetectable WT EGFR or EGFRvIII. We then treated GBM6
and GBM39 cells with the EGFR inhibitors AG1478 and Erlo-
tinib, the SFK inhibitors SU6656, PP2, its inactive stereoisomer
PP3, or vehicle control. These inhibitors markedly attenuated
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Fig. 4. EGFRvIII-induced p-Dock180Y722 is Src-dependent. (A) Inhibition of Src
by PP2 (2 μM) or SU6656 (2 μM) attenuates EGFRvIII-stimulated p-Y of Dock180
(detectedwith a pan-phospho-tyrosine antibody, 4G10) and Rac1 activity. (B) In
vitro cell migration. (C) Src phosphorylates Dock180 at Y722 by Src. Dock180WT
or Dock180Y722F and WT, a KD or a CA Src were separately coexpressed in
HEK293T cells. (D) Src-KD inhibits EGFRvIII-induced p-Dock180Y722. (E) In vitro
Src kinase assay. Various proteins were visualized by Coomassie brilliant blue
staining. (F) Src-dependent p-Y of Dock180 at Y722 enhances association of
Dock180 with Rac1. (G) Knockdown of Src inhibits EGFRvIII-induced p-
Dock180Y722 and Rac1 activation. (H) In vitro cell migration. In A and C–G,
Dock180, Src, Rac1, and β-actin were used as loading controls. In A, C, and D,
a pan anti–p-Y antibody (4G10) was used to detect p-Y of Dock180. (E–G) A
speciﬁc anti–p-Dock180Y722 antibody was used to detect p-Y722 of Dock180. In
B andH, data are presented as percentage of the control from six replicates per
pair per cell line. *P < 0.05 and **, P < 0.01. (Scale bars, ± SD.) Data represent
















































































































































Fig. 5. EGFRvIII-inducedp-Dock180Y722 is also dependent on SFKs, Fyn and Lyn.
(A and C) Knockdownof Lynor Fyn inhibits EGFRvIII-induced p-Dock180Y722 and
Rac1 activation. Dock180, Rac1, and β-actin were used as loading controls. (B
and D) In vitro cell migration assays; data are presented as percentage of the
control from six replicates per pair per cell line. *P < 0.05 and **, P < 0.01. (Scale
bars, ± SD.) Data represent three independent experiments with similar results.














Rac1 activity, and cell migration compared with GBM cells
treated with PP3 or vehicle control (Fig. S5 B and C). These
results further suggest that SFK-dependent p-Dock180Y722 is
critical for EGFRvIII-stimulated p-Akt, p-Erk1/2, Rac1 activity,
and cell migration in glioblastoma cells.
Coexpression of EGFRvIII, p-Dock180Y722 and pan-p-SrcY418 in Clinical
Glioblastoma Specimens Correlates with an Extremely Poor Prognosis.
We performed immunohistochemical (IHC) analysis using anti-
bodies against p-Dock180Y722, EGFRvIII, or p-SrcY418 (also
detects p-Y of other SFKs) on a cohort of 124 clinical glioblastoma
specimens with identiﬁable central and invasive regions (11). As
shown in Table S1, EGFRvIII protein was detected by the speciﬁc
anti–EGFRvIII-antibody DH8.3 (16) in 36 of 69 GBM (WHO
grade IV, 52.2%) and 5 of 26 WHO grade II (19.2%), and 5 of 29
WHO grade III (17.2%) glioblastoma samples, similar to the
frequency of EGFRvIII overexpression in clinical GBMs (2). Next,
we stained these 46 EGFRvIII-positive tumors and an additional
11 EGFRvIII-negative samples. As shown in Tables S1 and S2, the
majority of EGFRvIII-positive tumors demonstrated the presence
of p-Dock180Y722 and pan-p-SrcY418. Additionally, coexpression
of EGFRvIII, p-Dock180Y722 and pan-p-SrcY418 was found in
tumor cells within the invasive areas, as well as in the central
regions (Tables S1–S3). An example is shown in Fig. 6A, where
EGFRvIII was detected in both invasive (Fig. 6Aa) and central
regions (Fig. 6Ad) in a GBM specimen. Interestingly, both pan p-
SrcY418 and p-Dock180Y722 were also expressed in the majority of
EGFRvIII-positive tumor cells in invasive and central regions of
clinicalWHOgrade IV and II–III specimens (Fig. 6A, b, c, e, and f,
Fig. S6, and Table S1). In contrast, EGFRvIII, p-SrcY418 and p-
Dock180Y722 were not detected in normal brain tissues. Spear-
man’s rank correlation analysis of expression levels of EGFRvIII
and p-Dock180Y722 in all of these IHC-stained clinical specimens
showed correlation coefﬁcients between border vs. border regions
as 0.9000 (P < 0.05), center vs. center regions as 0.9747 (P < 0.05),
and invasive vs. invasive areas as 0.8721 (P < 0.05), respectively
(Tables S2 and S3).
To further validate these ﬁndings, we examined expression of
EGFRvIII, p-SrcY418, and p-Dock180Y722 in a separate and in-
dependent cohort of 38 clinical GBM specimens by IB analyses. As
shown in Fig. 6B, overexpression of EGFR and EGFRvIII was
detected in 10 of 38 (26.3%) GBMs, whereas EGFR was overex-
pressed in an additional twoGBMs, corroborating with the genetic
analyses using ﬂuorescent in situ hybridization. Dock180 was
expressed at high levels in 25 of 38 GBMs, whereas pan-p-SrcY418
was also found in 27 of 38 tumors. Signiﬁcantly, p-Dock180Y722
was coexpressed with pan-p-SrcY418 in 7 of 10 EGFR/EGFRvIII-
expressingGBMs (tumors 2, 5, 11, 12, 15, 33, and 38), suggestive of
the presence of activated EGFR/EGFRvIII-SFK-Dock180-Rac1
signaling in these GBMs. Additionally, Kaplan-Meier analyses
showed that in these two independent cohorts, patients with high
expression of EGFRvIII or p-Dock180Y722 have a shorter overall
survival compared with those with low expression of EGFRvIII
or p-Dock180Y722 (Fig. S7 A and B). In these cases, a statistically
signiﬁcant correlation was found between worse prognosis of
patients with high expression of p-Dock180Y722 compared with low
expression in the cohort that were analyzed by IHC staining (Fig.
S7A). When combining the expression status of EGFRvIII and
p-Dock180Y722 in the analyses, a statistically signiﬁcant worse
prognosis was apparent in glioblastomas with high expression of
both proteins compared with those with low expression in both
cohorts (Fig. 6C). Of note, compared with prognosis of glioblas-
tomas with individual high expression of either EGFRvIII or
p-Dock180Y722, the better prognosis value of high expression of
both proteins did not appear as drastic as we anticipated. However,
this is probably because of the fact that overexpression of
EGFRvIII is already a strong prognosis marker for malignant
glioblastomas (1, 3) and a relative small number of cases (38 GBM
samples) examined by IB analyses. Taken together, these data
suggest that p-Dock180Y722 could be an independent, as well as an
additional, clinically useful marker in the diagnosis and assess-
ment of outcome in GBM with EGFRvIII overexpression.
Discussion
In this study, we report that SFK-dependent p-Dock180Y722
mediates downstream EGFRvIII-signaling and glioblastoma
growth and invasion. This study highlights four important points.
First, Dock180 is required for EGFRvIII-stimulated glioblas-
toma cell migration and survival in vitro. Second, EGFRvIII
induces a speciﬁc p-Y of Dock180 at Y722 and mutation of this
p-Y site inhibits EGFRvIII-promoted glioblastoma cell migra-
tion and survival in vitro and tumor growth and invasion in vivo.
Third, SFKs, Src, Fyn, and Lyn mediate EGFRvIII induction of
phosphorylation of Dock180Y722 in glioblastoma cells stimulat-
ing tumorigenesis. Fourth, p-Dock180Y722 and p-SrcY418 are
coexpressed with EGFRvIII in clinical glioblastoma specimens.
Coexpression of EGFRvIII, p-Dock180Y722 and p-SrcY418 is
correlated with an extremely poor prognosis in patients with
glioblastomas. Taken together, our results suggest that SFK ac-
tivation of p-Dock180Y722-Rac1 signaling plays a critical role in
EGFRvIII-driven glioblastoma tumorigenesis.
GEFs couple RTKs to Rac1 (9) and Dock180 is a downstream
effector of EGFR-mediated cell migration in Drosophila (10).
Here, we show that EGFRvIII induces SFKs-dependent p-
DockY722, thereby activating Rac1-signaling and promoting glio-
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Fig. 6. Coexpression of p-Dock180Y722, EGFRvIII and p-SrcY418 correlates
with an extremely poor prognosis in patients with glioblastomas. (A) IHC
analysis. A total of 57 specimens that express EGFRvIII and/or p-Dock180Y722
and p-SrcY418 are listed in Table S1. Representative images of GBM (grade IV)
tissue stained by anti-EGFRvIII (a and d), anti–p-SrcY418 (b and e), and anti–
p-Dock180Y722 (c and f) antibodies. Arrows, positive staining for EGFRvIII,
p-SrcY418, and p-Dock180Y722. (Scale bars, 50 μm.) (B) IB analysis of a separate
and independent cohort of 38 snap-frozen GBM specimens. Dock180 and
β-actin were used as loading controls. (C) Kaplan-Meier curves with long-
rank analyses for patients with high EGFRvIII/p-Dock180Y722–expressing
tumors (red line) versus low-expression tumors (blue line) of two separate
cohorts of glioblastomas examined in A and B. P values were determined by
using the log-rank test. Black bars, censored data. Data represent three in-
dependent experiments with similar results.
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of Dock180 (8) and modulates cell growth, survival, and motility
(17). Consistent with this ﬁnding, inhibition of Dock180 by siRNA
knockdown, overexpression of a Dock180Y722F mutant, or sup-
pression of SFKs impaired EGFRvIII-stimulated Rac1 activity and
tumorigenesis. Moreover, EGFRvIII also activates the PI3K-Akt
and MAPK pathways (3, 4) and induces a cytokine circuit that
stimulates EGFR-signaling in neighboring tumor cells (18). Sepa-
rate disruption of these downstream pathways inhibits EGFRvIII
function, underscoring the heterogeneity of clinical glioblastomas.
This heterogeneity is also illustrated by the fact that activated
p-SrcY418 is detected in all 38 clinical glioblastoma samples,
whereas EGFRvIII and p-Dock180Y722 are only expressed in 8 of
38 specimens. Similarly, in a total of 124 clinical glioblastoma
specimens analyzed by IHC, p-Dock180Y722 and p-SrcY418were not
detected in a number of tumors that express EGFRvIII, suggesting
that other signaling pathways are also involved in EGFRvIII-driven
tumorigenesis. The heterogeneity of glioblastomas involved p-Y of
Dock180 is further demonstrated by our recent study, showing that
a Src-dependent p-Y of Dock180 mediates PDGFRα, another
RTK that is often overexpressed in proneural subtype of human
glioblasotmas (1–3), and promoted glioblastoma tumorigenesis.
Moreover, PDGFRα/Src-induced p-Y of Dock180 is at another
tyrosine residue of Dock180 (19), indicating a distinct signaling
from PDGFRα/Src. Taken together, our results show that SFK-
dependent p-Y of Dock180 mediates EGFRvIII and PDGFRα
stimulation of Rac1 signaling, cell growth, survival, and invasion
in glioblastomas.
Src, Lyn, and Fyn are expressed in clinical glioblastoma samples
and EGFRvIII-expressing glioblastoma cells. Inhibition of Src,
Lyn, or Fyn attenuated EGFRvIII-promoted tumorigenesis and
invasion (13, 14). Our data are consistent with and extend these
ﬁndings. We found that Src directly induces phosphorylation of
Dock180Y722 and interaction of Dock180 with Rac1 in vitro and
in glioblastoma cells. Moreover, inhibition of Src, Lyn, and Fyn
by pharmacological inhibitors or shRNA knockdown reduces
EGFRvIII-induced p-Dock180Y722, Rac1 signaling and migration
of glioblastoma cells. Coexpression of p-Dock180Y722, EGFR, and
EGFRvIII and p-SrcY418 in clinical glioblastoma tumor specimens
correlates with an extremely poor prognosis. Therefore, our re-
sults integrate SFK-activated p-Dock180Y722-Rac1 signaling in
EGFRvIII-driven tumorigenesis.
It has been postulated that nonstimulated Dock180 assumes an
inhibitory conﬁguration in which the SH3 domain folds back and
interacts with DHR-2 domain, preventing access of Rac1. Upon
ELMO1 binding, folded Dock180 is opened to allow Rac1 binding
to theDHR-2 domain (8). Similarly, the N terminus of a RhoGEF
Vav1 interacts with its Dbl homology (DH) domain, thereby
inhibiting GTPase binding (7). Moreover, a Src-induced p-Y of
Vav1 at its N terminus opens theDH domain for Rac1 binding (7).
Our data are consistent with this mechanism. We show that SFK-
dependent p-Dock180Y722 is required for Dock180 activation of
Rac1, thereby mediating EGFRvIII-promoted tumorigenesis.
However, Y722 is not located in the identiﬁed functional domains
but at the boundary of a helix/coil conﬁguration in the DHR-1/
DHR-2 interdomain of Dock180 (20). With the helix/coil repeats
of the interdomain, the DHR-1 domain is brought into close ap-
position with DHR-2 and Rac1, bringing the membrane binding
elements of DHR-1 and Rac1 into the same coplanarity, thereby
enabling simultaneous membrane association of the ELMO1-
Dock180-Rac1 complex. Additionally, a Dock180-Rac1 dimer is
formed that binds to the membrane (20). Therefore, SFK-induced
p-Y722 could be critical for the interdomain ofDock180 that holds
DHR-1 adjacent to DHR-2 to form a dimeric complex and to
achieve the activation of Rac1.
In summary, our data connect the sustained activation of
EGFRvIII and SFKs to the p-Dock180Y722 that stimulates Rac1
signaling and malignant behavior of human glioblastoma cells.
This unique link is underscored by coexpression of EGFRvIII, p-
SrcY418 and p-Dock180Y722 in clinical glioblastoma specimens and
association with extremely poor prognoses. Because activation of
EGFRvIII and SFKs renders an aggressive glioblastoma pheno-
type and the induced p-Y of Rho GEF is a common mechanism
that activates Rac1 signaling, our results suggest that targeting the
EGFRvIII-SFK-Dock180-Rac1 pathway could offer hope in
treating malignant glioblastomas with EGFRvIII overexpression.
Materials and Methods
For descriptions of cell lines, cell cultures, reagents, antibodies, DNA con-
structs, IB and IP, puriﬁcation of recombinant proteins, in vitro Src tyrosine
phosphorylation, pull-down assays of the binding of Dock180 with Rac1,
and statistical analysis, see SI Materials and Methods. Experiments using
animals were performed using a protocol that was reviewed and approved
by the University of Pittsburgh Institutional Animal Care and Use Committee.
Studies using human tissues were reviewed and approved by the Institutional
Review Board involving Human Subjects at the University of Pittsburgh,
Pittsburgh, PA.
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